Alumis Inc. (ALMS)
NASDAQ:ALMS
Want to see ALMS full AI Analyst Report?
ALMS Stock Chart & Stats
$24.99
-$0.47(-5.84%)
At close: 4:00 PM EST
$24.99
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $30.60
Previous CloseN/A
Volume29.29K
Average Volume (3M)1.59M
Market Cap
$3.24B
Enterprise Value$2.87B
Total Cash (Recent Filing)$308.50M
Total Debt (Recent Filing)$36.91M
Price to Earnings (P/E)―
Beta-1.45
Next Earnings
May 20, 2026EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.99
Shares Outstanding123,139,430
10 Day Avg. Volume2,295,855
30 Day Avg. Volume1,592,686
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)27.54
Price to Sales (P/S)345.07
P/FCF Ratio-22.42
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue119.46
Enterprise Value/Gross Profit123.93
Enterprise Value/Ebitda-6.94
Forecast
1Y Price Target
$40.88Price Target Upside63.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.95
Revenue Forecast (FY)$7.89M
Bulls Say, Bears Say
Bulls Say
EfficacyRobust Phase 3 results demonstrating consistently strong complete skin‑clearance across two pivotal trials strengthen confidence that envudeucitinib can compete effectively with leading oral psoriasis therapies.
Indication Expansion PotentialRegulatory validation of the TYK2 mechanism in joint disease and strong skin‑disease activity support the feasibility of expanding envudeucitinib into psoriatic arthritis and systemic lupus, increasing the program's long‑term opportunity.
Safety ProfileA generally clean safety profile with fewer adverse events and no meaningful laboratory abnormalities suggests reduced need for routine monitoring and may encourage prescriber adoption.
Bears Say
Competitive Pricing PressureIntense competition from established oral and biologic therapies, including rivals with convenient dosing or prior approval, could force lower pricing and shrink envudeucitinib's expected market share.
Data Transparency And ComparabilityLimited topline disclosure and omission of placebo and comparator response rates reduce visibility into placebo‑adjusted benefit and make cross‑trial comparisons difficult for clinicians and payers.
Regulatory And Commercialization UncertaintyUncertainty about potential label requirements, monitoring obligations, and regulatory timelines increases the risk of slower market uptake, potential approval delays, and equity dilution.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $30.60 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.24B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is May 20, 2026 which is in 12 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Mar 19, 2026. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.923 by $0.043.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.77.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 123,139,430 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.923. Following the earnings report the stock price went down -1.261%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.88 (63.57% Upside)
$40.88 (63.57% Upside)
Hedge Fund Trend
Decreased
By 1.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.50%
12-Months-Change
Fundamentals
Return on Equity
-72.65%
Trailing 12-Months
Asset Growth
22.04%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$40.88
▲(63.57% Upside)
Technical Analysis
Ownership Overview
56.33% Insiders
5.30% Mutual Funds
0.40% Other Institutional Investors
29.80% Public Companies and Individual Investors